Cartesian Therapeutics, Inc.RNACNASDAQ

Revenue (LTM)

$3M

-92.8% YoY

Net Income (LTM)

$-130M

-68.3% YoY

Free Cash Flow

$-79M

Revenue CAGR (5Y)

-30.0%

—Marginsstable

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	85	111↑30.2%	26↓76.5%	39↑49.6%	3↓92.8%
Gross Profit	85	109↑27.8%	26↓76.1%	39↑49.6%	3↓92.8%
Operating Income	-5	15↑416.2%	-86↓694.4%	-44↑49.2%	-87↓97.5%
Net Income	-26	35↑237.7%	-220↓721.0%	-77↑64.8%	-130↓68.3%
EBITDA	-5	40↑872.4%	-235↓690.0%	-76↑67.7%	-87↓14.1%
EPS Diluted	-6.60	3.00↑145.5%	-49.76↓1758.7%	-3.29↑93.4%	-5.02↓52.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	114	106↓6.7%	77↓27.7%	213↑176.4%	125↓41.1%
Total Current Assets	144	148↑2.6%	91↓38.8%	217↑138.8%	129↓40.3%
Total Assets	160	166↑3.8%	305↑83.9%	435↑42.6%	296↓31.9%
Total Current Liabilities	72	25↓65.3%	68↑172.0%	23↓66.3%	15↓35.0%
Total Liabilities	137	72↓47.5%	745↑934.2%	442↓40.7%	423↓4.3%
Total Equity	23	94↑316.6%	-440↓569.1%	-7↑98.5%	-126↓1755.9%
Total Debt	35	38↑7.5%	11↓71.1%	14↑27.6%	13↓9.4%
Net Debt	-79	-69↑13.0%	-66↑3.7%	-199↓201.1%	-112↑43.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-60	-32↑47.6%	-51↓61.7%	-24↑53.7%	-74↓212.3%
Capital Expenditure	-1	-1↓10.7%	-0↑82.8%	-9↓4314.1%	-5↑40.0%
Free Cash Flow	-61	-33↑46.6%	-51↓56.5%	-33↑36.2%	-79↓142.3%
Stock-Based Comp	8	11↑45.0%	23↑101.2%	7↓70.8%	11↑59.8%
Net Change in Cash	-25	-7↑70.0%	-30↓302.1%	136↑557.1%	-87↓164.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance